Last update 21 Nov 2024

Povetacicept

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
povetacicept
Mechanism
APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glomerulonephritis, IGAPhase 3
US
30 Aug 2024
Glomerular diseasePhase 2
AU
15 Mar 2023
Glomerulonephritis, MembranousPhase 2
KR
15 Mar 2023
Glomerulonephritis, MembranousPhase 2
US
15 Mar 2023
Glomerulonephritis, MembranousPhase 2
AU
15 Mar 2023
Glomerulonephritis, MembranousPhase 2
PR
15 Mar 2023
Lupus NephritisPhase 2
US
15 Mar 2023
Lupus NephritisPhase 2
AU
15 Mar 2023
Lupus NephritisPhase 2
PR
15 Mar 2023
Lupus NephritisPhase 2
KR
15 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Glomerulonephritis, IGA
galactose-deficient IgA1 (Gd-IgA1)
12
(vlnldiswrl) = Povetacicept has been well tolerated, with the majority of treatment-emergent adverse events being of low grade and none leading to treatment discontinuation or dose reduction/interruption. yzgmxidhjw (tltllbavke )
Positive
01 Apr 2024
Phase 1/2
13
(mhrgycgeij) = bcxxzscgos srtilzkhur (pdacsclpai )
Positive
02 Nov 2023
Phase 1/2
-
(raxmoqrtbl) = in the first IgAN dose cohort (80 mg subcutaneously once every 4 weeks) has been safe and well-tolerated to date, with no serious or severe adverse events, no events of hypogammaglobulinemia (IgG < 3g/L), and no instances of hypersensitivity or administration-related reactions. tuzeyjxkfb (xgdaorymga )
Positive
30 Aug 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free